

ChinaAMC Global ETF Series

**ChinaAMC Hang Seng Hong Kong
Biotech Index ETF**

Unaudited Semi-Annual Report

For the period from
1 January 2022 to 30 June 2022



华夏基金
ChinaAMC

UNAUDITED SEMI-ANNUAL REPORT

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(Stock Code: 03069 (HKD Counter) and 09069 (USD
Counter))
(a Sub-Fund of ChinaAMC Global ETF Series)

For the period from 1 January 2022 to 30 June 2022

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

CONTENTS

	Pages
MANAGEMENT AND ADMINISTRATION	1 – 2
REPORT OF THE MANAGER TO THE UNITHOLDERS	3
UNAUDITED FINANCIAL STATEMENTS	
Statement of financial position	4
Statement of comprehensive income	5 – 6
Statement of changes in net assets attributable to unitholders	7
Statement of cash flows	8
INVESTMENT PORTFOLIO (UNAUDITED)	9 – 10
MOVEMENTS IN INVESTMENT PORTFOLIO (UNAUDITED)	11 – 12
PERFORMANCE RECORD (UNAUDITED)	13
DISTRIBUTION DISCLOSURE (UNAUDITED)	14
INVESTMENT LIMITATION AND PROHIBITIONS UNDER THE SFC CODE (UNAUDITED)	15

IMPORTANT:

Any opinion expressed herein reflects the Manager's view only and is subject to change. For more information about the Sub-Fund, please refer to the prospectus of the Sub-Fund which is available at our website: (https://www.chinaamc.com.hk/en/products/etf/ChinaAMC_Hang_Seng_Hong_Kong_Biotech_Ind_ex ETF/documents.html)

Investors should not rely on the information contained in this report for their investment decisions.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

MANAGEMENT AND ADMINISTRATION

Manager

China Asset Management (Hong Kong) Limited
37/F, Bank of China Tower
1 Garden Road
Central, Hong Kong

Directors of the Manager

Yang Minghui (resigned on 30 March 2022)
Gan Tian
Li Yimei
Li Fung Ming
Sun Li Qiang (appointed on 30 March 2022)

Trustee & Registrar

HSBC Institutional Trust Services (Asia) Limited
1 Queen's Road
Central, Hong Kong

Auditor

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, One Taikoo Place
979 King's Road
Quarry Bay, Hong Kong

Conversion Agent

HK Conversion Agency Services Limited
1/F One & Two Exchange Square
8 Connaught Place
Central, Hong Kong

Listing Agent

Altus Capital Limited
21 Wing Wo Street
Central, Hong Kong

Legal Adviser to the Manager

Simmons & Simmons
30/F, One Taikoo Place
979 King's Road
Hong Kong

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

MANAGEMENT AND ADMINISTRATION (continued)

Participating Dealers

ABN AMRO Clearing Hong Kong Limited
70/F, International Commerce Centre
1 Austin Road West
Kowloon, Hong Kong

BNP Paribas Securities Services
21/F, PCCW Tower
Taikoo Place
979 King's Road
Hong Kong

China Merchants Securities (HK) Co., Limited
48/F, One Exchange Square
8 Connaught Place
Central, Hong Kong

Goldman Sachs (Asia) Securities Limited
68/F, Cheung Kong Center
2 Queen's Road
Central, Hong Kong

Huatai Financial Holdings (Hong Kong) Limited
62/F, The Center
99 Queen's Road Central
Central, Hong Kong

Haitong International Securities Company Limited
22/F Li Po Chun Chambers
189 Des Voeux Road
Central, Hong Kong

The Hongkong and Shanghai Banking Corporation
Limited
1 Queen's Road Central
Hong Kong

Korea Investment & Securities Asia Limited
Suite 3716-19, Jardine House
1 Connaught Place
Central, Hong Kong

The Hongkong and Shanghai Banking Corporation
Limited
Level 18 HSBC Main Building
1 Queens's Road
Central
Hong Kong

J.P. Morgan Broking (Hong Kong) Limited
25/F, Chater House
8 Connaught Road
Central
Hong Kong

China International Capital Corporation Hong Kong
Securities Limited
29/F, One IFC
1 Harbourview Street
Central
Hong Kong

Credit Suisse Securities (Hong Kong) Limited
Level 88
International Commerce Centre
1 Austin Road West, Kowloon
Hong Kong

Citigroup Global Markets Asia Limited
50th Floor, Champion Tower
Three Garden Road
Central
Hong Kong

Guotai Junan Securities (Hong Kong) Limited
27/F, Low Block
Grand Millennium Plaza
No.181 Queen's Road Central
Hong Kong

Mirae Asset Securities (Hong Kong) Limited
Units 8501,8507-08, Level 85
International Commerce Centre
1 Austin Road West, Kowloon
Hong Kong

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

REPORT OF THE MANAGER TO THE UNITHOLDERS

Introduction

The ChinaAMC Hang Seng Hong Kong Biotech Index ETF (the “Sub-Fund”) is a sub-fund of ChinaAMC Global ETF Series, an umbrella unit trust established under Hong Kong law by a trust deed dated 17 September 2015 between China Asset Management (Hong Kong) Limited (the “Manager”) and HSBC Institutional Trust Services (Asia) Limited (the “Trustee”). The Sub Fund is a passively-managed ETF falling within Chapter 8.6 and the Code on Unit Trusts and Mutual Funds issued by the SFC. Units of the Sub-Fund (the “Units”) are traded on The Stock Exchange of Hong Kong Limited (the “SEHK”) like stocks. The Sub-Fund’s HKD counter (stock code: 3069) commenced trading on the SEHK on 18 March 2021 and USD counter (stock code: 9069) commenced trading on the SEHK on 30 June 2021. The Sub-Fund is an index-tracking fund that seeks to track the performance of the Hang Seng Hong Kong-Listed Biotech Index (the “Index”).

The Manager primarily uses a full replication strategy through investing directly in Securities included in the Index with substantially the same weightings in which they are included in the Index.

The Manager may also use a representative sampling strategy where it is not possible to acquire certain Securities which are constituents of the Index due to restrictions or limited availability or where the Manager considers appropriate in its absolute discretion. This means that the Sub-Fund will invest directly in a representative sample of Securities that collectively has an investment profile that aims to reflect the profile of the Index. The Securities constituting the representative sample may or may not themselves be constituents of the Index, provided that the sample closely reflects the overall characteristics of the Index. In pursuing a representative sampling strategy, the Manager may cause the Sub-Fund to deviate from the index weighting on condition that the maximum deviation from the index weighting of any constituent will not exceed 4% or such other percentage as determined by the Manager after consultation with the SFC.

Performance of the Sub-Fund

The investment objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Index. There can be no assurance that the Sub-Fund will achieve its investment objective.

The performance of the Sub-Fund is in below (Total Returns in respective currency²):

	1-Month	3-Month	Since Launch
The Index	14.91%	4.05%	-43.67% ³
HKD Counter of the Sub-Fund (NAV-to-NAV)	15.00%	3.80%	-43.98% ²
HKD Counter of the Sub-Fund (Mark-to-Market)	15.28%	3.59%	-44.07% ²
USD Counter of the Sub-Fund (NAV-to-NAV)	15.02%	3.58%	-52.85% ⁴
USD Counter of the Sub-Fund (Mark-to-Market)	15.80%	3.22%	-52.86% ³

Activities of the Sub-Fund

According to Bloomberg, the average daily trading volume of the Sub-Fund was 88,348 units from 01 January 2022 to 30 June 2022. As of 30 June 2022, there were 70,200,000 units outstanding.

China Asset Management (Hong Kong) Limited
16 August 2022

² Source: Bloomberg, as of 30 June 2022. Performances of the benchmark Index and HKD Counter of the Sub-Fund are calculated in HKD while performances of USD Counter of the Sub-Fund are calculated in USD. Past performance figures shown are not indicative of the future performance of the Sub-Fund. With effect from 8 November 2021, the investment strategy of the Fund was changed. The performance of the Fund prior to 8 November 2021 was achieved under circumstances that no longer apply.

³ Calculated since 18 March 2021.

⁴ Calculated since 30 June 2021.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

STATEMENT OF FINANCIAL POSITION (UNAUDITED)

As at 30 June 2022

	30 June 2022 (Unaudited) HKD	31 December 2021 (Audited) HKD
ASSETS		
Financial assets at fair value through profit or loss	950,030,923	1,191,135,035
Amount due from Manager	-	40,000
Prepayments and other receivables	8,191	44,206
Dividend Receivables	3,468,123	-
Cash and cash equivalents	1,701,075	5,240,170
TOTAL ASSETS	<u><u>955,208,312</u></u>	<u><u>1,196,459,411</u></u>
LIABILITIES		
Amounts due to brokers	1,023,184	-
Management fee payable	352,619	527,859
Trustee and registrar fees payable	72,067	87,855
Other payables and accruals	218,658	382,046
TOTAL LIABILITIES	<u><u>1,666,528</u></u>	<u><u>997,760</u></u>
EQUITY		
Net asset value attributable to unitholders	<u><u>953,541,784</u></u>	<u><u>1,195,461,651</u></u>
TOTAL LIABILITIES AND EQUITY	<u><u>955,208,312</u></u>	<u><u>1,196,459,411</u></u>
Number of units in issue	<u><u>70,200,000</u></u>	<u><u>71,800,000</u></u>
Net asset value per unit	<u><u>13.5832</u></u>	<u><u>16.6499</u></u>

Note: The semi-annual report of the sub-funds have been prepared in accordance with the same accounting policies adopted in the 2021 annual financial statements.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)

For the period from 1 January 2022 to 30 June 2022

	Period from 1 January 2022 to 30 June 2022 (Unaudited) HKD	Period from 18 March 2021 (date of inception) to 31 December 2021 (Audited) HKD
INCOME		
Dividend income	6,652,552	9,129,319
Interest income	14	170
Other income	147,260	795,339
	<u>6,799,826</u>	<u>9,924,828</u>
EXPENSES		
Management fee ^{Note 2}	(2,236,046)	(6,477,017)
Trustee and registrar fees ^{Note 1}	(378,203)	(1,073,754)
Accounting fees ^{Note 1}	(34,812)	(46,800)
Auditor's remuneration	(61,648)	(114,000)
Transaction fees ^{Note 1}	(302,310)	(3,082,989)
Legal and professional fees	(43,238)	(88,703)
Safe custody and bank charges ^{Note 1}	(107,418)	(235,951)
Formation costs	-	(705,000)
Other operating expenses	(327,234)	(809,869)
	<u>(3,490,909)</u>	<u>(12,634,083)</u>
PROFIT/(LOSS) BEFORE INVESTMENT LOSSES AND EXCHANGE DIFFERENCES	3,308,917	(2,709,255)
INVESTMENT LOSSES AND EXCHANGE DIFFERENCES		
Net realised losses on financial assets at fair value through profit or loss	(62,763,231)	(48,421,587)
Net change in unrealised losses on financial assets at fair value through profit or loss	(150,033,233)	(569,063,359)
Foreign exchange differences	(158)	(162)
	<u>(212,796,622)</u>	<u>(617,485,108)</u>
LOSS BEFORE TAX	(209,487,705)	(620,194,363)
Withholding tax expense	(277,342)	(384,306)
TOTAL COMPREHENSIVE INCOME	<u>(209,765,047)</u>	<u>(620,578,669)</u>

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED) (Continued)

For the period from 1 January 2022 to 30 June 2022

^{Note 1} During the period ended 30 June 2022, trustee and registrar fees, accounting fees and safe custody and bank charges incurred were paid to the Trustee or its connected person. Other respective amounts paid to the Trustee or its connected person were as follows:

	Period from 1 January 2022 to 30 June 2022 (Unaudited) HKD	Period from 18 March 2021 (date of inception) to 31 December 2021 (Audited) HKD
Transaction fees	21,253	118,863

^{Note 2} During the period ended 30 June 2022, other than management fees that paid to the Manager, no other amounts paid to the Manager or its connected persons.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS
(UNAUDITED)

For the period from 1 January 2022 to 30 June 2022

	Units	HKD
Balance at the beginning of the period	71,800,000	1,195,461,651
Issue of units during the period	2,200,000	29,071,960
Redemption of units during the period	(3,800,000)	(61,226,780)
Total comprehensive income	-	(209,765,047)
Balance at the end of the period	<u>70,200,000</u>	<u>953,541,784</u>

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

STATEMENT OF CASH FLOWS (UNAUDITED)

For the period from 1 January 2022 to 30 June 2022

	Period from 1 January 2022 to 30 June 2022 (Unaudited) HKD	Period from 18 March 2021 (date of inception) to 31 December 2021 (Audited) HKD
CASH FLOWS FROM OPERATING ACTIVITIES		
Loss before tax	(209,487,705)	(620,194,363)
Adjustments for:		
Dividend income	(6,652,552)	(9,129,319)
Interest income	(14)	(170)
	<u>(216,140,271)</u>	<u>(629,323,852)</u>
Decrease/(increase) in financial assets at fair value through profit or loss	241,104,112	(489,419,475)
Decrease/(increase) in amount due from Manager	40,000	(40,000)
Decrease/(increase) in prepayments and other receivables	36,015	(44,206)
Decrease in amount due to broker	1,023,184	-
(Decrease)/increase in management fee payable	(175,240)	527,859
(Decrease)/increase in trustee and registrar fees payable	(15,788)	87,855
(Decrease)/increase in other payables and accruals	(163,388)	382,046
	<u>25,708,624</u>	<u>(1,117,829,773)</u>
Cash generated from/(used in) operations		
Dividend received	3,184,429	9,129,319
Interest received	14	170
Tax paid	(277,342)	(384,306)
	<u>28,615,725</u>	<u>(1,109,084,590)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issue of units*	29,071,960	1,381,314,160
Payments on redemption of units*	(61,226,780)	(266,989,400)
	<u>(32,154,820)</u>	<u>1,114,324,760</u>
Net cash flows (used in)/from financing activities		
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	(3,539,095)	5,240,170
Cash and cash equivalents at the beginning of the period	5,240,170	-
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	<u>1,701,075</u>	<u>5,240,170</u>
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS		
Cash at bank	<u>1,701,075</u>	<u>5,240,170</u>

* During the period, there were no non-cash transactions on proceeds from issue of units and on payments on redemption of units.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

INVESTMENT PORTFOLIO (UNAUDITED)

As at 30 June 2022

	Holdings	Fair value HKD	% of Net Assets
Listed equities			
<u>Hong Kong</u>			
Consumer, Cyclical			
Alibaba Health Information Technology Ltd	5,567,464	30,064,306	3.15
JD Health International Inc	1,318,860	81,175,833	8.51
Shanghai Pharmaceuticals Holding Co Ltd	919,446	11,952,798	1.25
Consumer, Non-cyclical			
3Sbio Inc	1,578,761	9,851,469	1.03
AK Medical Holdings Ltd	656,729	3,861,566	0.41
Akeso Inc	529,315	12,200,711	1.28
Alphamab Oncology	551,502	4,461,651	0.47
Antengene Corp Ltd	586,603	4,135,551	0.43
Ascentage Pharma Group International	216,583	4,613,218	0.49
Beigene Ltd	100,004	9,850,394	1.03
Brii Biosciences Ltd	765,119	6,472,907	0.68
Cansino Biologics Inc	109,300	8,782,255	0.92
Carsgen Therapeutics Holdings Ltd	367,761	5,376,666	0.56
China Medical System Holdings Ltd	1,590,332	19,465,664	2.04
China Resources Pharmaceutical Group Ltd	2,218,232	11,823,177	1.24
Clover Biopharmaceuticals Ltd	81,561	320,535	0.03
CSPC Pharmaceutical Group Ltd	10,557,178	82,240,417	8.63
Cstone Pharmaceuticals	1,328,599	6,975,145	0.73
Everest Medicines Ltd	177,361	3,990,622	0.42
Frontage Holdings Corp	1,098,983	3,439,817	0.36
Genscript Biotech Corp	1,612,572	45,877,673	4.81
Grand Pharmaceutical Group Ltd	1,880,131	8,535,795	0.90
Hangzhou Tigermed Consulting Co Ltd	144,913	13,143,609	1.38
Hansoh Pharmaceutical Group Co Ltd	1,393,124	22,067,084	2.31
Hutchmed China Ltd	661,247	12,788,517	1.34
Immunotech Biopharm Ltd	120,792	643,821	0.07
Innocare Pharma Ltd	970,524	12,985,611	1.36
Innovent Biologics Inc	1,556,493	54,321,606	5.70
Jinxin Fertility Group Ltd	2,208,499	15,967,448	1.68
Junshi Bio	193,588	8,179,093	0.86
JW Cayman Therapeutics Co Ltd	359,931	2,915,441	0.31
Kangji Medical Holdings Ltd	512,922	3,995,662	0.42
Keymed Biosciences Inc	213,769	7,054,377	0.74
Kintor Pharmaceutical Ltd	296,686	5,548,028	0.58
Lepu Biopharma Co Ltd	94,690	655,255	0.07
Lifetech Scientific Corp	4,632,168	13,386,965	1.40
Livzon Pharmaceutical Group Inc	184,317	5,004,207	0.53
Luye Pharma Group Ltd	2,709,372	6,990,180	0.73

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

INVESTMENT PORTFOLIO (UNAUDITED) (continued)

As at 30 June 2022

	Holdings	Fair value HKD	% of Net Assets
Listed equities (continued)			
Hong Kong (continued)			
Consumer, Non-cyclical (continued)			
Microport Cardioflow Medtech Corp	1,414,533	4,427,488	0.46
Microport Scientific Corp	1,072,142	24,391,230	2.56
Microport Scientific Corp Nil Paid Rights 31/12/2049	391	0	0.00
New Horizon Health Ltd	303,648	7,166,093	0.75
Ocumension Therapeutics	353,311	4,960,486	0.52
Peijia Medical Ltd	557,351	4,325,044	0.45
Pharmaron Beijing Co Ltd	224,729	17,652,463	1.85
Remegen Co Ltd	145,049	6,374,904	0.67
Shandong Weigao Group Medical Polymer Co Ltd	2,927,308	26,697,049	2.80
Shanghai Fosun Pharmaceutical Group Co Ltd	584,510	16,980,015	1.78
Shanghai Microport Medbot Group Co Ltd	22,203	690,513	0.07
Sihuan Pharmaceutical Holdings Group Ltd	4,941,037	6,324,527	0.66
Simcere Pharmaceutical Group Ltd	776,925	6,681,555	0.70
Sino Biopharmaceutical Ltd	13,326,887	66,234,628	6.95
Sinopharm Group Co Ltd	1,579,145	30,035,338	3.15
Sirnaomics Ltd	26,200	2,194,250	0.23
SSY Group Ltd	1,585,652	6,643,882	0.70
United Laboratories Ltd	1,182,264	5,497,528	0.58
Venus Medtech Hangzhou Inc	415,465	7,270,637	0.76
Viva Biotech Holdings	1,024,593	2,786,893	0.29
Wuxi Apptec Co Ltd	416,346	43,508,157	4.56
Wuxi Biologics Cayman Inc	1,289,332	92,574,038	9.71
Zai Lab Ltd	205,575	5,499,131	0.58
Total investments, at fair value		950,030,923	99.63
Total investments, at cost		1,669,194,836	

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

MOVEMENTS IN INVESTMENT PORTFOLIO (UNAUDITED)

For the period from 1 January 2022 to 30 June 2022

	Holdings as at 1 January 2022	Additions	Disposals	Corporate Actions	Holdings as at 30 June 2022
Listed equities					
<u>Hong Kong</u>					
3Sbio Inc	1,849,120	52,010	322,369	-	1,578,761
AK Medical Holdings Ltd	673,857	26,554	43,682	-	656,729
Akeso Inc	394,806	155,428	20,919	-	529,315
Alibaba Health Information Technology Ltd	5,709,215	240,334	382,085	-	5,567,464
Alphamab Oncology	566,159	23,287	37,944	-	551,502
Antengene Corp Ltd	527,250	87,264	27,911	-	586,603
Ascentage Pharma Group International	222,800	8,982	15,199	-	216,583
Beigene Ltd	102,706	4,132	6,834	-	100,004
Brii Biosciences Ltd	392,000	399,367	26,248	-	765,119
Cansino Biologics Inc	120,224	3,641	14,565	-	109,300
Carsgen Therapeutics Holdings Ltd	342,983	47,423	22,645	-	367,761
China Medical System Holdings Ltd	1,639,255	65,812	114,735	-	1,590,332
China Resources Pharmaceutical Group Ltd	2,278,860	91,965	152,593	-	2,218,232
CK Life Sciences International (Holdings) Inc	3,485,015	-	3,485,015	-	-
Clover Biopharmaceuticals Ltd	-	82,061	500	-	81,561
CSPC Pharmaceutical Group Ltd	10,857,877	445,880	746,579	-	10,557,178
Cstone Pharmaceuticals	1,359,958	58,094	89,453	-	1,328,599
Everest Medicines Ltd	179,834	9,046	11,519	-	177,361
Frontage Holdings Corp	1,115,657	58,378	75,052	-	1,098,983
Genor Biopharma Holdings	363,158	1,002	364,160	-	-
Genscript Biotech Corp	1,649,526	72,370	109,324	-	1,612,572
Grand Pharmaceutical Group Ltd	1,930,963	77,869	128,701	-	1,880,131
Hangzhou Tigermed Consulting Co Ltd	148,859	6,039	9,985	-	144,913
Hansoh Pharmaceutical Group Co Ltd	1,431,258	57,657	95,791	-	1,393,124
Hutchmed China Ltd	679,487	27,208	45,448	-	661,247
Immunotech Biopharm Ltd	-	120,792	-	-	120,792
Innocare Pharma Ltd	816,057	294,654	140,187	-	970,524
Innovent Biologics Inc	1,586,869	72,123	102,499	-	1,556,493
Jacobio Pharmaceuticals Group Co Ltd	419,639	-	419,639	-	-
JD Health International Inc	1,348,318	57,406	86,864	-	1,318,860
Jinxin Fertility Group Ltd	2,273,665	86,661	151,827	-	2,208,499

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

MOVEMENTS IN INVESTMENT PORTFOLIO (UNAUDITED)

For the period from 1 January 2022 to 30 June 2022

	Holdings as at 1 January 2022	Additions	Disposals	Corporate Actions	Holdings as at 30 June 2022
Listed equities (continued)					
Hong Kong (continued)					
Junshi Bio	198,857	8,057	13,326	-	193,588
JW Cayman Therapeutics Co Ltd	339,728	38,696	18,493	-	359,931
Kangji Medical Holdings Ltd	529,907	21,059	38,044	-	512,922
Keymed Biosciences Inc	186,000	40,111	12,342	-	213,769
Kintor Pharmaceutical Ltd	351,500	12,787	67,601	-	296,686
Lepu Biopharma Co Ltd	-	94,690	-	-	94,690
Lifetech Scientific Corp	4,756,896	193,041	317,769	-	4,632,168
Livzon Pharmaceutical Group Inc	189,359	7,671	12,713	-	184,317
Luye Pharma Group Ltd	2,782,829	112,331	185,788	-	2,709,372
Microport Cardioflow Medtech Corp	1,307,437	176,294	69,198	-	1,414,533
Microport Scientific Corp	1,100,192	45,166	73,216	-	1,072,142
Microport Scientific Corp Nil Paid Rights 31/12/2049	-	-	-	391	391
New Horizon Health Ltd	207,837	106,793	10,982	-	303,648
Ocumension Therapeutics	423,433	24,279	94,401	-	353,311
Peijia Medical Ltd	565,891	27,442	35,982	-	557,351
Pharmaron Beijing Co Ltd	153,914	9,235	10,251	71,831	224,729
Remegen Co Ltd	137,286	15,040	7,277	-	145,049
Shandong Weigao Group Medical Polymer Co Ltd	3,007,185	121,267	201,144	-	2,927,308
Shanghai Fosun Pharmaceutical Group Co Ltd	600,486	24,311	40,287	-	584,510
Shanghai Microport Medbot Group Co Ltd	-	22,203	-	-	22,203
Shanghai Pharmaceuticals Holding Co Ltd	1,000,022	29,939	110,515	-	919,446
Sihuan Pharmaceutical Holdings Group Ltd	5,140,358	204,725	404,046	-	4,941,037
Simcere Pharmaceutical Group Ltd	791,506	35,314	49,895	-	776,925
Sino Biopharmaceutical Ltd	13,673,091	574,411	920,615	-	13,326,887
Sinopharm Group Co Ltd	1,622,356	65,450	108,661	-	1,579,145
Sirnaomics Ltd	-	26,200	-	-	26,200
SSY Group Ltd	1,647,154	63,632	125,134	-	1,585,652
United Laboratories Ltd	1,223,994	41,041	82,771	-	1,182,264
Venus Medtech Hangzhou Inc	426,534	17,503	28,572	-	415,465
Viva Biotech Holdings	1,050,088	47,080	72,575	-	1,024,593
Wuxi Aptec Co Ltd	447,217	18,403	49,274	-	416,346
Wuxi Biologics Cayman Inc	1,285,923	291,967	288,558	-	1,289,332
Zai Lab Ltd	16,898	363,675	174,998	-	205,575
Total of equity securities	<u>89,629,253</u>	<u>5,613,252</u>	<u>10,874,700</u>	<u>72,222</u>	<u>84,440,027</u>

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

PERFORMANCE RECORD (UNAUDITED)

For the period from 1 January 2022 to 30 June 2022

1. Net Asset Value

	Net asset value per unit HKD	Total net asset value HKD
As at:		
30 June 2022 (Unaudited)	13.5832	953,541,784
31 December 2021 (Audited)	16.6499	1,195,461,651

2. Highest issue and lowest redemption prices per unit

	Highest issue unit price HKD	Lowest redemption unit price HKD
Period from 1 January 2022 to 30 June 2022 (Unaudited)	16.8542	10.1150
Period from 18 March 2021 (date of inception) to 31 December 2021 (Audited)	29.2558	15.9905

3. Comparison of the scheme performance and the actual index performance ¹

The table below illustrates the comparison between the Sub-Fund's performance (Market-to-Market) and that of the index during the following periods:

	The index	HKD counter of the Sub-Fund	USD counter of the Sub-Fund
Period from 1 January 2022 to 30 June 2022 (Unaudited)	-18.14%	-18.00%	-18.24%
Period from 18 March 2021 (date of inception) to December 2021 ² (Audited)	-31.18%	-31.80%	-42.34%

¹ Past performance figures shown are not indicative of the future performance of the Sub-Fund.

² The performance of the USD counter of the Sub-Fund covers the period from 30 June 2021 to 31 December 2021.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

DISTRIBUTION DISCLOSURE (UNAUDITED)

For the period from 1 January 2022 to 30 June 2022

The Manager may in its absolute discretion distribute income to unitholders at such time or times as it may determine in each financial period or determine that no distribution shall be made in any financial period. The amount to be distributed to unitholders, if any, will be derived from the net income of the Sub-Fund.

The Sub-Fund did not make any distribution during the period ended 30 June 2022.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF
(a Sub-Fund of ChinaAMC Global ETF Series)

INVESTMENT LIMITATION AND PROHIBITIONS UNDER THE SFC CODE (UNAUDITED)

As at 30 June 2022

Pursuant to the SFC's Guidelines for Regulating Index Tracking Exchange Trade Funds, the Sub-Fund's holding of any such constituent securities should not exceed their respective weightings in the underlying index, except where the weightings are exceeded as a result of changes in the composition of the underlying index and the excess is only transitional and temporary in nature.

The Sub-Fund did not have any constituent securities that individually accounted for more than 10% of the NAV of the Sub-Fund and its respective weightings of the Index as at 30 June 2022.



华夏基金(香港)有限公司
CHINA ASSET MANAGEMENT (HONG KONG) LIMITED

www.ChinaAMC.com.hk

37/F, Bank of China Tower, 1 Garden Road, Hong Kong

Customer Service Hotline: (852) 3406 8686